Why Hims & Hers' Incredible Growth Will Continue
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.
HIMS: GLP-1 Is Just The Beginning
Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue growth and 270% EBITDA increase, signaling strong financial health and future potential.
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
Hims & Hers Health (HIMS) shares surged Monday after the Food and Drug Administration (FDA) said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage of their active ingredient.
FDA Buzz Sends Health and Wellness Stock Surging
Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA).
Where Does Hims & Hers Stock Go From Here?
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?
2 Incredibly Cheap Growth Stocks to Buy Right Now
Look beyond the stock price at the business when shares are volatile.
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Consistently investing even moderate sums can grow your portfolio with time.
Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S&P 500 index. However, there is still a preference for the technology sector, and this preference is now being diversified away from the semiconductor industry and into other niches.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over
Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly's obesity and diabetes drugs are no longer facing supply constraints, and have been removed from the shortage list.
